A Phase 3 clinical trial, JADE COMPARE, evaluating Pfizer's (NYSE:PFE) JAK1 inhibitor abrocitinib in patients with moderate-to-severe atopic dermatitis met both co-primary endpoints of response rate as measured by two scales, IGA and EASI-75, at week 12 versus placebo.

The data, along with results from two other pivotal trials, will support a U.S. marketing application, expected to be filed later this year.

Shares down 3% after hours.

READ FULL ARTICLE HERE